p16INK4A, an inhibitor of cyclin‐dependent kinase (CDK), modulates the RB tumour suppressor pathway by restraining cyclin D1‐CDK4 mediated RB phosphorylation, thereby exerting pivotal influence on cell cycle regulation and differentiation [28], its downregulation subsequent to SNF5 (it is encoded by the SMARCB1) inactivation is associated with tumorigenesis [28]. Here, SMARCB1 is linked to neoplasm.